⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 3, 2024Open Access

Supplementary Figure S3 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Mark Jesus M. Magbanua Ziad Ahmed Rosalyn W. Sayaman Lamorna Brown Swigart Gillian L. Hirst Christina Yau Denise M. Wolf Wen Li Amy L. Delson Jane Perlmutter Paula R. Pohlmann W. Fraser Symmans Douglas Yee Nola M. Hylton Laura J. Esserman Angela DeMichele Hope S. Rugo Laura van ‘t Veer

View Full Paper

Ask AI

Bookmark

Share

Abstract

Association between pretreatment cfDNA concentration and clinicopathologic variables. CfDNA concentration was measured in pretreatment plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancers (TNBC). P values were calculated using the Wilcoxon rank sum test.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Magbanua et al. (2024) studied this question.

synapsesocial.com/papers/68e66839b6db6435875f3c6a https://doi.org/10.1158/1078-0432.25956229

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy2024
2Supplementary Figure S2 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy2024
3Supplementary Figure S2 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy2024
4Supplementary Figure S1 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy2024
5Supplementary Figure S1 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy2024

More related papers

Supplementary Figure S6 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy2024
Supplementary Figure S6 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy2024
Supplementary Figure S4 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy2024